133407-82-6

Basic information

• Product Name: MG-132
• Synonyms: PROTEASOME INHIBITOR MG-132;N-[(PHENYLMETHOXY)CARBONYL]-L-LEUCYL-N-[(1S)-1-FORMYL-3-METHYLBUTYL]-L-LEUCINAMIDE;N-CBZ-LEU-LEU-LEUCINAL;MG-132;Z-LLL-CHO;Z-LL-CHO;Z-LEU-LEU-LEU-CHO;Z-LEU-LEU-LEU-H
• CAS NO: 133407-82-6
• Molecular Formula: C26H41N3O5
• Molecular Weight: 475.62
• Product Categories: Cytokine signaling;Apoptosis Inducers;API;Aldehydes;and Substrates;Application Index;Bioactive Small Molecules;Biochemicals and Reagents;Building Blocks;C13-C60;Calpain and Lysosomal Proteases;Calpain and Proteasome Inhibitors;Carbonyl Compounds;Cell Biology;Cell Signaling and Neuroscience;Cell Signaling Enzymes;Chemical Synthesis;Enzymes;Inhibitors;Intracellular Protein Degradation;Nitric Oxide and Cell Stress;Organic Building Blocks;Proteasome;Proteasomes;Z;ProteasomeInhibitors;peptides;inhibitor
• Mol File: 133407-82-6.mol
• Article Data: 9

Chemical Properties

• Melting Point: 80-84℃ (DEC.)
• Boiling Point: 682 °C at 760 mmHg
• Flash Point: 366℃
• Appearance: White/solid film
• Density: 1.073
• Vapor Pressure: 1.86E-18mmHg at 25°C
• Refractive Index: 1.506
• Storage Temp.: −20°C
• Solubility: methanol: 1 mg/mL
• PKA: 11.14±0.46(Predicted)
• Water Solubility: Soluble in ethanol, chloroform, methanol, water.
• Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO, DMF or ethanol may be stored at -20° for up to 1 week.
• CAS DataBase Reference: MG-132(CAS DataBase Reference)
• NIST Chemistry Reference: MG-132(133407-82-6)
• EPA Substance Registry System: MG-132(133407-82-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 24/25
• WGK Germany: 3
• Hazardous Substances Data: 133407-82-6(Hazardous Substances Data)

Usage

Description

MG-132 (133407-82-6) is a specific inhibitor of the chymotrypsin-like activity of the 20S proteasome (IC50=100 nM with Z-LLL-AMC as substrate).1 Also inhibits calpain (IC50=1.25 μM).1 Suppresses gastric cancer cell proliferation and induces macro-autophagy.2 Activates stress kinases and induces Hsp72.3 Induces neurite outgrowth.1 MG-132 blocks NFκB activation by blocking IκB proteolysis (IC50=3 μM).4 Cell permeable.

Uses

Different sources of media describe the Uses of 133407-82-6 differently. You can refer to the following data:
1. A proteasome and NF-κB inhibitor.
2. MG 132 is a potent, membrane-permeable proteasome inhibitor. It induces neurite outgrowth in PC12 cells. Neuroprotective product.

Definition

ChEBI: A tripeptide that is L-leucyl-L-leucyl-L-leucine in which the C-terminal carboxy group has been reduced to the corresponding aldehyde and the N-terminal amino group is protected as its benzyloxycarbonyl derivative.

General Description

Potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable stains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1) and inhibits NF-κB activation (IC50 = 3 μM).

Biological Activity

Potent cell-permeable inhibitor of proteasome (IC 50 = 100 nM) and calpain (IC 50 = 1.2 μ M). Inhibits TNF- α -induced NF- κ B activation and I κ B α degradation. Induces neurite outgrowth in PC12 cells and has anticancer properties in vitro .

Biochem/physiol Actions

Cell permeable: yes

References

1) Tsubuki et al. (1996), Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine; J. Biochem.,? 119 572 2) Wu? et al. (2010), Macroautophagy and ERK phosphorylation counteract the antiproliferative effect of proteasome inhibitor in gastric cancer cells; Autophagy, 6 228 3) Meriin? et al. (1998), Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis; J. Biol. Chem., 273 6373 4) Fiedler et al. (1998), Inhibition of TNF-alpha-induced NF-kappaB activation and IL-8 release in A549 cells with the proteasome inhibitor MG-132; Am. J. Respir. Cell Mol. Biol., 19 259

InChI:InChI=1/C26H41N3O5/c1-17(2)12-21(15-30)27-24(31)22(13-18(3)4)28-25(32)23(14-19(5)6)29-26(33)34-16-20-10-8-7-9-11-20/h7-11,15,17-19,21-23H,12-14,16H2,1-6H3,(H,27,31)(H,28,32)(H,29,33)/t21-,22-,23-/m0/s1

Upstream product

• 1228687-82-8 C₂₆H₄₃N₃O₅ 
• 1211877-30-3 C₂₆H₄₃N₃O₅ 
• 7801-71-0 N-benzyloxycarbonyl-L-leucyl-L-leucine 
• 1211877-22-3 ((S)-1-(((S)-1-(((S)-1-hydroxy-4-methylpentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)amino)-4-methyl-1-oxopentan-2-yl)carbamic acid benzyl ester 
• 170590-15-5 Z-L-leucine-L-leucine-L-leucine N,O-dimethylhydroxylamide 
• 1161015-91-3 {1-[1-(1-hydroxymethyl-3-methylbutylcarbamoyl)-3-methylbutylcarbamoyl]-3-methylbutyl}carbamic acid benzyl ester 
• 82010-31-9 (S)-(1-hydroxymethyl-3-methylbutyl)carbamic acid tert-butyl ester 
• 13139-15-6 N-tert-butoxycarbonyl-L-leucine 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 3504-37-8 Cbz-L-Leu-L-Leu-OMe 
• 2018-66-8 Z-Leu-OH 
• 61-90-5 L-leucine 
• 7533-40-6 (S)-2-amino-4-methylpentan-1-ol 
• 1334176-70-3 C₂HF₃O₂*C₁₂H₂₆N₂O₂ 

Relevant articles and documents

Application of proteasome inhibitor in inhibition of novel coronavirus

The invention provides application of a proteasome inhibitor in inhibition of a novel coronavirus or preparation of novel coronavirus inhibitors. The proteasome inhibitor has a structure represented by a formula (I) or isomers, pharmaceutically acceptable salts thereof and prodrugs thereof. According to the application, by applying the proteasome inhibitor to inhibition of the novel coronavirus, good inhibiting activity is obtained, and a novel treatment way of think is provided for diseases such as pneumonia caused by the novel coronavirus.

Systematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motif

The ubiquitin-proteasome system (UPS) has been successfully targeted by both academia and the pharmaceutical industry for oncological and immunological applications. Typical proteasome inhibitors are based on a peptidic backbone endowed with an electrophi

Synthesis and SAR study of novel peptide aldehydes as inhibitors of 20S proteasome

Based on the analysis of the crystal structure of MG101 (1) and 20S proteasomes, a new series of peptide aldehyde derivatives were designed and synthesized. Their ability to inhibit 20S proteasome was assayed. Among them, Cbz-Glu(OtBu)-Phe-Leucinal (3c), Cbz-Glu(OtBu)-Leu-Leucinal (3d), and Boc-Ser(OBzl)-Leu-Leucinal (3o) exhibited the most activity, which represented an order of magnitude enhancement compared with MG132 (2). The covalent docking protocol was used to explore the binding mode. The structure-activity relationship of the peptide aldehyde inhibitors is discussed.